Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Protection against stroke with glucagon-like peptide-1 receptor agonists: a comprehensive review of potential mechanisms
Bruno Vergès, Victor Aboyans, Denis Angoulvant, et al.
Cardiovascular Diabetology (2022) Vol. 21, Iss. 1
Open Access | Times Cited: 27

Showing 1-25 of 27 citing articles:

Glucagon-like peptide-1 receptor: mechanisms and advances in therapy
Zhikai Zheng, Zong Yao, Yiyang Ma, et al.
Signal Transduction and Targeted Therapy (2024) Vol. 9, Iss. 1
Open Access | Times Cited: 97
Endothelial dysfunction in vascular complications of diabetes: a comprehensive review of mechanisms and implications
Dongrong Yang, Meng‐Yan Wang, Chenglin Zhang, et al.
Frontiers in Endocrinology (2024) Vol. 15
Open Access | Times Cited: 37
GLP-1 receptor agonists and atherosclerosis protection: the vascular endothelium takes center stage
Brady Park, Ehab Bakbak, Hwee Teoh, et al.
AJP Heart and Circulatory Physiology (2024) Vol. 326, Iss. 5, pp. H1159-H1176
Closed Access | Times Cited: 16
Combination treatment of SGLT2i and GLP-1RA associated with improved cardiovascular outcomes in type 2 diabetes patients with acute coronary syndrome: A propensity score-matched cohort study
Tao Liu, Zeyuan Fan, Yuntao Li, et al.
International Journal of Cardiology (2025), pp. 133229-133229
Open Access | Times Cited: 1
Glucagon-like peptide-1 receptor agonists and the risk of atrial fibrillation in adults with diabetes: a real-world study
Yunwen Xu, Thomas A. Boyle, Beini Lyu, et al.
Journal of General Internal Medicine (2024) Vol. 39, Iss. 7, pp. 1112-1121
Closed Access | Times Cited: 5
Do SGLT2 inhibitors and GLP-1 receptor agonists modulate differently the risk of stroke ? Discordance between randomised controlled trials and observational studies
André Scheen
Diabetes & Metabolism (2023) Vol. 49, Iss. 5, pp. 101474-101474
Closed Access | Times Cited: 11
Stroke and associated comorbidities in Southeast Asian countries
Aishika Datta, Soumya Akundi, Kaveri Wagh, et al.
Neuroprotection/Neuroprotection (Chichester, England. Print) (2025)
Open Access
Stroke in the Patient with Type 2 Diabetes
Terri Jerkins, David S.H. Bell
Endocrine Practice (2025)
Closed Access
Polyethylene Glycol Loxenatide Accelerates Diabetic Wound Healing by Downregulating Systemic Inflammation and Improving Endothelial Progenitor Cell Functions
Zerui Ding, Chunru Yang, Xiaojun Zhai, et al.
International Journal of Molecular Sciences (2025) Vol. 26, Iss. 5, pp. 2367-2367
Open Access
Incretin-based therapeutics for the treatment of neurodegenerative diseases
Anika Vear, Michael T. Heneka, Christoffer Clemmensen
Nature Metabolism (2025)
Closed Access
Severity of Chronic Kidney Disease as Assessed by the Kidney Failure Risk Equation Is Associated With Incident Acute Ischemic Stroke
Benjamin Yong‐Qiang Tan, Yong Yi Tan, Sean H. Lim, et al.
Nephrology (2025) Vol. 30, Iss. 2
Closed Access
Role of Residual Inflammation as a Risk Factor Across Cardiovascular-Kidney-Metabolic (CKM) Syndrome: Unpacking the Burden in People with Type 2 Diabetes
Roya Ghafoury, Mojtaba Malek, Faramarz Ismail‐Beigi, et al.
Diabetes Therapy (2025)
Open Access
Beyond antithrombotics: recent advances in pharmacological risk factor management for secondary stroke prevention
Dimitrios Sagris, George Ntaios, Haralampos Milionis
Journal of Neurology Neurosurgery & Psychiatry (2023) Vol. 95, Iss. 3, pp. 264-272
Open Access | Times Cited: 7
Advances in neuroprotective therapy for acute ischemic stroke
Yang Yang, Dandan Guo, Yiming Liu, et al.
Exploration of Neuroprotective Therapy (2024), pp. 55-71
Open Access | Times Cited: 2
Glucagonlike peptide‐1 receptor agonists versus dipeptidyl peptidase‐4 inhibitors in ischemic strokes with diabetes 2
Sidsel Hastrup, Jakob Nebeling Hedegaard, Grethe Andersen, et al.
European Journal of Neurology (2024) Vol. 31, Iss. 8
Open Access | Times Cited: 2
Incretin-Based Multi-Agonist Peptides Are Neuroprotective and Anti-Inflammatory in Cellular Models of Neurodegeneration
Katherine O. Kopp, Yazhou Li, Elliot J. Glotfelty, et al.
Biomolecules (2024) Vol. 14, Iss. 7, pp. 872-872
Open Access | Times Cited: 2
Glucagon-Like Peptide-1 Inhibits the Progression of Abdominal Aortic Aneurysm in Mice: The Earlier, the Better
Xinghan Zhao, Cheng Zhang, Hongbo Zhang, et al.
Cardiovascular Drugs and Therapy (2023) Vol. 38, Iss. 5, pp. 873-884
Open Access | Times Cited: 4
Systemic Oxidative Stress in Subacute Stroke Patients Undergoing Rehabilitation Treatment
Carola Cocco, Mariacristina Siotto, Alessandro Guerrini, et al.
Antioxidants (2024) Vol. 13, Iss. 3, pp. 354-354
Open Access | Times Cited: 1
Diabetes and Stroke: Impact of Novel Therapies for the Treatment of Type 2 Diabetes Mellitus
Inês Vieira, Tânia Carvalho, Joana Saraiva, et al.
Biomedicines (2024) Vol. 12, Iss. 5, pp. 1102-1102
Open Access | Times Cited: 1
To the Brain and Beyond: Neurological Implications of Glucagon-Like Peptide-1 Receptor Agonists
Lindsay R. Hunter Guevara, William B. Beam, Jeffrey J. Pasternak
Journal of Neurosurgical Anesthesiology (2024) Vol. 36, Iss. 4, pp. 278-282
Closed Access | Times Cited: 1
Budget impact analysis for three glucagon-like peptide-1 receptor agonist-based therapies for type 2 diabetes mellitus management in Saudi Arabia
Hussain Abdulrahman Al‐Omar, Hind Almodaimegh, Abubker Omaer, et al.
Journal of Medical Economics (2024) Vol. 27, Iss. 1, pp. 418-429
Open Access
AVC, nouveaux traitements : place des agonistes du récepteur du GLP-1
Bruno Vergès
Médecine des Maladies Métaboliques (2024)
Open Access
Geriatric Pharmacotherapy Case Series: Medications for Diabetes—A Focus on Secondary Stroke Prevention
Sabrina Warren, Shayla McKee, Erin Yakiwchuk
The Senior Care Pharmacist (2024) Vol. 39, Iss. 10, pp. 350-359
Closed Access
Glucagon-like peptide 1 receptor agonists modestly reduced low-density lipoprotein cholesterol and total cholesterol levels independent of weight reduction: a meta-analysis and meta-regression of placebo controlled randomized controlled trials
Frederick Berro Rivera, Melanie Chin, Polyn Luz S Pine, et al.
Current Medical Research and Opinion (2024), pp. 1-16
Closed Access
A glükagonszerűpeptid-1-receptor-agonisták cardio- és neuroprotectiv szerepe a 2-es típusú diabetest kísérő ischaemiás stroke előfordulásának mérséklésében
Gábor Winkler, András Folyovich, János Tibor Kis, et al.
Orvosi Hetilap (2024) Vol. 165, Iss. 13, pp. 489-498
Open Access
Page 1 - Next Page

Scroll to top